Tempus makes $1.5B bet to corner cancer-test market
Tempus AI (TEM) spent three years selling someone else's cancer test. On Monday, July 20, it decided to just buy the whole thing. The AI diagnostics company agreed to acquire Personalis (PSNL) in a deal valued at $1.5 billion. The move hands Tempus full control of a test that spots cancer ...
Read the full story at TST (Full) - (Official Feed) →